Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer

… with ALK-positive advanced non-small cell lung cancer (NSCLC). These results demonstrated that … of Medicine. About Non-Small Cell Lung Cancer Lung cancer is the leading cause of … American Cancer Society. Detailed Guide: Lung Cancer (Non-Small Cell). Available at: http …